Physician profile
Roy D Gerard
NPI 1922157809
$584.89
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2020: $96.73 · 2021: $19.69 · 2022: $37.06 · 2023: $154 · 2024: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $243 · Education: $18.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $242.96 |
| Education | $18.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $150.75 | 2019-2024 | Krystexxa, Tavneos |
| Glaxosmithkline, LLC. | $92.68 | 2022-2024 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $84.17 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $52.41 | 2019 | |
| Opko Pharmaceuticals, LLC | $32.87 | 2019-2023 | Rayaldee |
| Vifor Pharma, INC. | $27.00 | 2023 | Veltassa |
| Alnylam Pharmaceuticals INC. | $25.51 | 2023 | Oxlumo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.16 | 2024 | Jardiance |
| Mallinckrodt Hospital Products INC. | $20.15 | 2020 | |
| Aurinia Pharma U.S., INC. | $19.69 | 2021 | |
| Shire North American Group INC | $19.63 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $19.60 | 2019 | |
| Veloxis Pharmaceuticals, INC. | $17.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Gerard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.